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Mice lacking the vesicular glutamate transporter-3
(VGLUT3) are congenitally deaf due to loss of gluta-
mate release at the inner hair cell afferent synapse.
Cochlear delivery of VGLUT3 using adeno-associ-
ated virus type 1 (AAV1) leads to transgene expres-
sion in only inner hair cells (IHCs), despite broader
viral uptake. Within 2 weeks of AAV1-VGLUT3
delivery, auditory brainstem response (ABR) thresh-
olds normalize, alongwith partial rescue of the startle
response. Lastly, we demonstrate partial reversal of
the morphologic changes seen within the afferent
IHC ribbon synapse. These findings represent a
successful restoration of hearing by gene replace-
ment in mice, which is a significant advance toward
gene therapy of human deafness.
INTRODUCTION
Hearing loss is one of the most common human sensory deficits,
with congenital hearing loss occurring in approximately 1.5 in
1,000 children (Smith et al., 2005). Of these, about half are attrib-
uted to a genetic basis (Di Domenico et al., 2011). While our
understanding of the causes of genetic hearing loss has
advanced tremendously over the past 30 years (Petersen and
Willems, 2006), treatments have advanced little over this same
time period and currently consist of hearing amplification for
mild to severe losses and cochlear implantation for severe to
profound losses (Kral and O’Donoghue, 2010). Though cochlear
implantation has profoundly influenced our treatment of children
with congenital deafness, there are still significant limitations in
function with an implant, and these results cannot compare to
native hearing (Kral and O’Donoghue, 2010). Thus, there remains
intense interest in restoring normal organ of Corti function
through techniques such as hair cell regeneration and gene
therapy (Di Domenico et al., 2011). To date, a majority of the
research in this arena has focused on cochlear hair cell regener-
ation, applicable to the most common forms of hearing lossincluding presbycusis, noise damage, infection, and ototoxicity.
Several studies have now demonstrated regeneration of hair
cells in injured mice cochlea and improvement of both hearing
and balance with virally mediated delivery of Math1 (Baker
et al., 2009; Husseman and Raphael, 2009; Izumikawa et al.,
2008; Kawamoto et al., 2003; Praetorius et al., 2010; Staecker
et al., 2007). While these efforts in wild-type animals are quite
important, they still do not address the problem of an underlying
causative genetic mutation. In such a scenario, even success-
fully regenerated hair cells will still be subject to the innate
genetic mutation that led to hair cell loss in the first place. To
date, efforts to restore hearing in this type of hearing loss with
gene therapy have been met with limited success (Maeda
et al., 2009), and no study has reported the reversal of deafness
in an animal model of genetic deafness.
Previous reports have described a mouse model of hereditary
deafness, which occurs as a result of a null mutation in the
gene coding for the vesicular glutamate transporter-3 (VGLUT3)
(Obholzer et al., 2008; Ruel et al., 2008; Seal et al., 2008).
Synaptic transmission mediated by glutamate requires transport
of the excitatory amino acid into secretory vesicles by a family of
three vesicular glutamate transporters (Fremeau et al., 2004;
Takamori et al., 2002). We previously demonstrated that inner
hair cells of the cochlea express VGLUT3 and that mice lacking
this transporter are congenitally deaf (Seal et al., 2008). Hearing
loss in these mice is due to the elimination of glutamate release
by inner hair cells and hence to the loss of synaptic transmission
at the IHC-afferent nerve synapse. Subsequent studies have
shown that a missense mutation in the human gene SLC17A8,
which encodes VGLUT3, might underlie the progressive high-
frequency hearing loss seen in autosomal dominant DFNA25
(Ruel et al., 2008). Here we report the successful restoration of
hearing in the VGLUT3 knockout (KO) mouse using virally
mediated gene delivery.
RESULTS
AAV1-VGLUT3 Transfection Results in Localized
Expression in Inner Hair Cells
Our first goal was to determine the extent of transfection with the
adeno-associated virus type 1 (AAV1) within the cochlea. UsingNeuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc. 283
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Hearing Restoration in the VGLUT3 KO Mousean AAV1-GFP construct, there appeared to be labeling of
a variety of cell types within the cochlea, including the inner
hair cells and supporting cells using an anti-GFP antibody (Fig-
ure 1A), in a pattern similarly described by other investigators
(Jero et al., 2001; Konishi et al., 2008). Subsequently, virus con-
taining the VGLUT3 gene (AAV1-VGLUT3) was microinjected
into the cochlea using two different techniques: initially via an
apical cochleostomy (CO) and subsequently by direct injection
through the round window membrane (RWM) (Figures 1B–1E).
After delivery, RT-PCR of inner ear tissue (Figure 1C) demon-
strated strong VGLUT3 mRNA expression in the rescued whole
cochlea, organ of Corti, stria vascularis, vestibular neuroepithe-
lium, and very weakly in the spiral ganglion. Noninjected
cochleas of knockouts do not demonstrate VGLUT3 expression
as noted (Figure 1C, KO /+RT). In contrast, under immunofluo-
rescence, inner hair cells were the only cells labeled with anti-
VGLUT3 antibody (Figure 1B).
To determine the dose dependence of VGLUT3 expression
in the IHCs, we injected either 0.6 ml or 1 ml of AAV1-VGLUT3
(2.3 3 1013 virus genomes [vg]/ml) into the cochlea (Figures 1D
and 1E). Microinjecting 1 ml of virus resulted in 100% of IHCs
labeled with anti-VGLUT3 antibody; in contrast, microinjecting
0.6 ml resulted in only 40% of IHCs labeled by the antibody.
We next sought to determine whether earlier viral delivery
would result in more robust VGLUT3 expression (Figures 1D,
1E, and 2). As shown, delivery of virus via the RWM at postnatal
day 10 (P10) results in 40% of the IHCs expressing VGLUT3
(Figures 1D, 1E, and 2), whereas similar doses (0.6 ml) of virus
injected at P1–P3 results in 100% of IHC transfected in all
animals (Figures 1D, 1E, and 2).
Delivery of AAV1-VGLUT3 Restores Normal ABR and
CAP Thresholds within 14 Days
After verifying successful transgene expression within the IHC
without significant organ of Corti injury, we next sought to deter-
mine whether the reintroduction of VGLUT3 would lead to meas-
ureable hearing recovery (Figure 3). In these studies, only 0.6 ml
of AAV1-VGLUT3 was delivered at P10–P12. Auditory brainstem
response (ABR) thresholds were first measurable within 7 days
after viral delivery, with near normalization of thresholds
to wild-type (WT) levels within 2 weeks (P24–P26) (Figures
3A–3C). Initially a CO technique was used for viral delivery.
However, this method restored hearing in only 17% of animals
(n = 5 out of 30 animals attempted), presumably because it was
more technically challenging and due to the trauma of the
approach (see Discussion). As a result, the method was subse-
quently changed to an RWM delivery, which resulted in hearing
restoration in 100% of mice (n = 19 out of 19 mice). The time
course of hearing recovery was similar for the CO (when
successful in 17%) and the RWM delivery techniques (100% of
mice). Compound action potentials (CAPs) were also restored
within 7–14 days of viral delivery (Figure 3A). Since the loss of
VGLUT3 affects only glutamate release at the IHC synapse
(Ruel et al., 2008; Seal et al., 2008), restoration of normal ABRs
and CAPs also implies restoration of synaptic function. We
also compared the longevity of hearing recovery, defined as
the period of time between onset of hearing recovery and
when ABR thresholds become elevated >10 dB aboveWT levels,284 Neuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc.between the CO and RWMmethods (Figure 3D). In both groups,
all rescued KO mice maintained hearing for at least 7 weeks. At
28 weeks postdelivery, 40% of the mice who achieved suc-
cessful CO delivery still had hearing within 10 dB of WT mice
(n = 2/5), while only 5% of the RWM mice had the same level
of hearing (n = 1/19). Interestingly, some rescued mice in each
group, CO and RWM, maintained normal ABR thresholds up to
1.5 years. The number of animals for each rescued group at
each time point, within 10 dB of WT thresholds, is described in
the legend of Figure 3D.
We subsequently measured hearing recovery in mice injected
via the RWM at P1–P3 (Figure 3D). Due to the small size of the
cochlea, only 0.6 ml of virus could be delivered at this time point.
However, 100% of mice recovered normal ABR thresholds by
P14 (n = 19 mice). Five mice were followed for 9 months and still
maintained normal ABR thresholds at this later time point. Earlier
delivery thus not only appears to be more efficient (100% of
animals recover hearing) but also leads to greater longevity of
hearing recovery.
Bilateral AAV1-VGLUT3 Rescue Results in a Larger
Recovery of Behavioral and Electrical Measures
of Hearing
For an additional assay of hearing recovery, we studied the
startle response at approximately 3 weeks after viral delivery
(Figure 4). In these experiments, the AAV1-VGLUT3 delivery
was done via the RWM at age P10–P12. As expected, VGLUT3
KOmice show no startle response due to the absence of hearing.
When hearing was rescued in one ear (‘‘unilat,’’ Figure 4A), at the
loudest presentation level of 120 dB, the startle response
improved to 8% of normal, while if both ears were rescued
(‘‘bilat,’’ Figure 4A), the startle response increased to 33% of
normal, both measures being statistically different than the KO
response. Interestingly, similar amplitude growth was observed
with ABR wave I amplitudes when both ears, as opposed to
a single ear, were rescued (Figure 4B). ABR wave I latency was
also studied (Figure 4C), and while there appeared to be a trend
for reduced latency in the unilateral-rescued mice, the differ-
ences between unilateral- and bilateral-rescued and WT mice
were not significant. Thus, while ABR thresholds can be brought
to normal, ‘‘behavioral’’ thresholds and ABR amplitudes can be
improved, but not normalized, to the WT level with this rescue
technique.
AAV1-VGLUT3 Rescue Partially Restores Synaptic
Morphology, but Not Spiral Ganglion Cell Counts,
in the Knockout Mouse
As we previously demonstrated (Seal et al., 2008), at P21,
VGLUT3 KO mice show a 10%–18% decrease in spiral ganglion
(SG) neurons compared to WT mice. This decrease was still
observed in the AAV1-VGLUT3 rescued mice (RWM delivery at
P10–P12) at P21 (Figure 5A). Further, rescued mice showed no
significant differences in spiral ganglion cell size as compared
to KO mice (Figure 5B), though both were significantly less
than WT mice. To determine whether long-term hearing would
reverse this trend, we also took counts at 5 months after birth,
but again, no significant differences in SG counts or cell size
were seen in the KO versus rescued mice at this later time point
Figure 1. AAV1-GFP Transduction in Mice Organ of Corti
(A) AAV1-GFPwas used to assess viral delivery to the cochlea on organ of Corti surface preparations. AAV1 transfects a number of cell types including inner (IHC)
and supporting cells (white arrows, left) in the organ of Corti. The VGLUT3 KO (V3KO, middle) documents IHC labeling of transfected cells only. In the WTmouse
(right), VGLUT3 colabels IHCs (red) along AAV1-GFP-transfected cells (green).
(B) VGLUT3 expression after AAV1-VGLUT3 delivery via the RWM, delivered at P10–P12, and stained with anti-myosin 7A antibody (green, used as a hair cell
marker, left column) and anti-VGLUT3 antibody (red, middle column) and merged (right column). WTmice show IHCs labeled with both anti-Myo7A and VGLUT3
as expected (top row, right), whereas KO mice only show Myo7a expression (middle row, right). After AAV1-VGLUT3 delivery, the IHC is colabeled by both
anti-Myo7a and anti-VGLUT3 antibodies (bottom row, right) (TC, tunnel of Corti; DC, Deiter’s cells; OHC, outer hair cells; IHC, inner hair cells).
(C) RT-PCR was used to verify VGLUT3 mRNA expression in the transfected KO (first lane) and WT (second lane) mice. Rescued whole cochlear extract (R-Co)
demonstrates strong VGLUT3 mRNA expression, as does the stria vascularis + organ of Corti lane (R-SV+OC) and vestibular neuroepithelium (R-Vest). Spiral
ganglion only shows weak mRNA expression (R-SG).
(D and E) Inner hair cells labeled with anti-VGLUT3 antibody after transfection were counted, tabulating both the entire cochlea and within the base, midturn, and
apex to determine differences in regions (at P10–P12 delivery, WT n = 5, CO n = 5, RWM n = 6 and at P1–P3 delivery, RWM n = 6). At P10–P12, when 1 ml of virus
was microinjected, 100% of IHCs were labeled and similar results were seen at P1–P3 viral delivery (D) when injected with 0.6 ml. In contrast, when 0.6 ml of virus
was injected at P10–P12, approximately 40% of IHCs were labeled, with no significant differences seen between the apex, midturn, or base in the variability of
IHC labeling with the delivery technique (E).
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Figure 2. VGLUT3 IHC Transfection: Early versus Late Delivery
AAV1-VGLUT3 delivery at P1–P3 versus P10–P12 are compared using similar amount of virus (0.6 ml) and examined at P30. Anti-Myo7a antibody (green) and
anti-VGLUT3 antibody (red) are used for staining, and the merged images (yellow) are shown. As expected, IHC from WT mice show both anti-Myo7a and anti-
VGLUT3 staining (row 1), whereas KO mice only show anti-Myo7a label (row 2). Delivery of virus via the RWM at P10–P12 results in fewer IHCs expressing
VGLUT3 (row 3), whereas similar doses of virus injected at P1–P3 results in 100% of hair cells transfected in all animals (row 4) (IHC, inner hair cells).
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also undertaken in mice that underwent virus delivery at P1–P3.
However, despite a robust IHC transfection and early hearing
recovery (see Figures 1D, 1E, and 2), again, no differences in
SG cell counts were noted between KO and rescued mice
(data not shown). Additionally, histology (Figure 5C) documents
no obvious cochlear trauma as a result of viral delivery in the
rescued mice, as evidenced by normally appearing organ of
Corti structures with preservation of inner and outer hair cells,
supporting cells, spiral ganglion neurons (though similarly
reduced in number as nonrescuedmice), and the stria vascularis
(data not shown).
As originally reported, VGLUT3 KO mice demonstrate abnor-
mally thin, elongated ribbons in IHC synapses, though the
number of synaptic vesicles tethered to ribbons or docked at
the plasma membrane was normal (Seal et al., 2008). We thus
sought to determine whether these morphologic abnormalities
could be reversedwith hearing rescue. As shown (Figure 6, Table
1), in the rescued mice, ribbon synapses are normal in appear-
ance, taking on a more rounded shape similar to the WT, while
the nonrescued mice continue to demonstrate abnormally thin
and elongated ribbons. The rescuedmice also displayed a signif-
icantly larger number of synaptic vesicles associated with the
ribbon (19 rescued versus 14 WT, p = 0.02) (Table 1). Interest-286 Neuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc.ingly, within individual hair cells, the synaptic vesicles them-
selves demonstrated a mixture of elongated and circular mor-
phology, as opposed to all circular in the WT and all elongated
in the KO mice. However, when analyzing the average number
of docked synaptic vesicles at a ribbon synapse, rescued
animals did not show a significant difference between the WT
and KO mice (Table 1). While these results demonstrate only
a partial reversal of the synaptic changes seen in the KO mouse
ribbon synapse, it is enough to recover ABR thresholds to theWT
levels in the rescued KO mice.
DISCUSSION
These studies document the successful rescue of the deafness
phenotype in a mouse model of inherited deafness. With viral
delivery of VGLUT3 at P10–P12 in the KO mouse, ABR thresh-
olds normalize within 7–14 days and remain in this range for at
least 7 weeks, with two mice maintaining auditory thresholds
for as long as a year and a half in this current study. Earlier
delivery, at P1–P3, results in an even more robust IHC transfec-
tion and long-lived hearing recovery in this mouse model.
One unexpected result from these investigations was the
differential finding of more widespread expression of green fluo-
rescent protein (GFP) after AAV1-GFP transfection as compared
Figure 3. Hearing Restoration in the VGLUT3 KO Mice
(A) Representative ABR and CAP tracings fromWT, KO, and rescued KO mice after delivery of 0.6 ml AAV1-VGLUT3. Waveforms from the WT and rescued mice
appear similar, while KO mice show no ABR and no CAP responses. ‘‘I’’ indicates the location of ABR wave I.
(B) Rescued mice begin to show hearing recovery within 7 days postdelivery (P17–P19), with near normalization of ABR thresholds by 14 days postdelivery
(P24–P26). Hearing recovery is seen with both CO and RWM delivery through 69 weeks. Black arrows indicate absence of ABR threshold of the KO above 92 dB
(the maximum level that our recording equipment can measure).
(C) At 40 days postdelivery (P50–P52), similar levels of recovery are noted at 8 and 16 kHz, while at 32 kHz, CO delivery appears to result in slightly elevated
thresholds, though still significantly better than KO.
(D) Hearing longevity, as defined as the number of mice with ABR threshold levels within 10 dB of WT levels at each time point, is measured for RWM at P10–P12,
CO at P10–P12, and RWM at P1–P3. For viral delivery at P10–P12, CO delivery results in longer-lasting hearing recovery on average than RWM delivery, with
some rescued KO in each group maintaining ABR thresholds to within 10 dB of WT animals beyond 28 weeks. However, 100% of rescued KO mice with RWM
delivery recover hearing, while only 17% of CO-rescued mice recover hearing. The number of animals with viral delivery at P10–P12 at each time point is the
following: RWM 0–9 weeks n = 19, 10–13 weeks n = 12, 14–24 weeks n = 8, 24–28 weeks n = 1, 28+ weeks n = 1; CO 0–7 weeks n = 5, 8–14 weeks n = 4,
15–20 weeks n = 3, 21–28 weeks n = 2, 28+ weeks n = 1. In contrast, in mice undergoing viral delivery at P1–P3, all animals maintain ABR threshold recovery at
least through 9 months (n = 5).
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AAV1-VGLUT3 transfection (Figures 1A–1C and 2). RT-PCR
results demonstrate that after AAV1-VGLUT3 delivery, there is
also more widespread VGLUT3 mRNA transcription than in just
IHCs (Figure 1C). These results suggest that there is a posttran-
scriptional regulatory mechanism acting on VGLUT3 mRNA,
which leads to selective expression of the protein only within
IHCs. Several types of posttranscriptional regulation have been
described within the cochlea, and whether this specific mecha-
nism involves microRNA inactivation (Elkan-Miller et al., 2011),
transcription factor regulation (Masuda et al., 2011), or another
process remains to be determined. Such a mechanism, if appro-
priately elucidated and exploited, could theoretically allow theexpression (or conversely suppression) of a number of different
proteins within the inner ear to alter function in pursuit of hearing
preservation.
Another interesting finding was the variable success with the
CO as compared to the RWM delivery technique. As noted, we
initially started with an apical CO delivery method but aban-
doned it due to the low success rate of hearing restoration
(17% of animals). Subsequently, we changed to an RWM
delivery technique for several reasons; this would be the most
likely method of delivery in any future human studies, and it
was less likely to be traumatic, as evidenced by a number of
recent human studies looking at hearing preservation with round
window insertion of cochlear implants (von Ilberg et al., 2011). InNeuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc. 287
Figure 4. Behavioral Measures and Physiologic Growth after AAV1-VGLUT3 Rescue
(A) Startle responses were studied as an additional behavioral measure of hearing recovery 3 weeks after viral delivery (P31–P33). While none of the rescuedmice
recover startle responses to WT levels, they nonetheless develop a response, which increases when both ears are rescued; the louder the sound delivered (100,
110, and 120 dB presentation levels), themore robust the startle response was, with rescue of both ears (bilat) creating a larger response than a single ear (unilat).
These differences were statistically significant.
(B) Similar growth was seen for ABR wave I amplitudes when both ears (bilat) as compared to a single ear (unilat) were rescued, though again not as robust as in
the WT mice.
(C) ABRwave I latency wasmeasured, which showed no statistically significant differences between unilateral, bilateral, rescued, andWTmice, though there was
a trend toward an increased latency in the rescued compared to WT mice.
(D) Representative ABR tracings documenting increasing wave I amplitudes from the KO, unilaterally rescued KO (unilat), bilaterally rescued KO (bilat), and WT
mice.
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100% of animals attempted. We believe the likely difference in
success between the two techniques relates to the degree of
trauma induced by each method. With a cochleostomy, a sepa-
rate hole into the scala through bone must be created, which by
its nature is traumatic, despite our best efforts to minimize
trauma. In contrast, an RWM injection simply involves piercing
the membrane and sealing it with fascia after viral delivery.
However, we were histologically unable to see any obvious
differences between the ears of animals with andwithout hearing
rescue in the cochleostomy group (data not shown) and there
may be other reasons for the variable success between the
two techniques. Further, we noted that even earlier delivery via
the RWM at P1–P3, as opposed to P10–P12, resulted in hearing
recovery that was more consistently long lived, with all mice288 Neuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc.followed out through 9 months showing ongoing normal ABR
thresholds (Figure 3D).
Transgene expression with AAV1 should theoretically last for
a year or longer (Henckaerts and Linden, 2010). However, it is
not entirely clear why there is a variable loss of hearing after
7 weeks, regardless of delivery technique at the later P10–P12
delivery time point (Figure 3D). We analyzed individual cochleae
but did not see histologic evidence of active inflammation in
those animals that lost hearing and IHCs still expressing VGLUT3
protein. Further, spiral ganglion counts did not significantly differ
in animals with and without hearing. One possibility could be due
to the trauma of viral delivery, with gradual reopening of the
delivery site (RWM or cochleostomy) leading to a perilymphatic
leak with resulting hearing loss. Such a lesion might not be
detectable on histology. Another possible explanation may be
Figure 5. Spiral Ganglion Cell Counts
In these studies, the AAV1-VGLUT3 delivery was done at P10–P12 and at P1–P3. Spiral ganglion (SG) cell counts in rescued mice versus KO and WT mice were
undertaken at P21 (A and B) and at 5 months after birth (data not shown) for P10–P12 virus delivery and at twomonths after birth (data not shown) for P1–P3 virus
delivery. AAV1-VGLUT3 transfection did not result in a reversal of the SG neuronal loss in either age group. No significant differences were seen between the
groups. These results also document the lack of trauma (C) associated with virally mediated delivery of VGLUT3 through the RWM, with normal organ of Corti
morphology, including inner and outer hair cells, spiral ganglion neurons, and stria vascularis (data not shown).
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as microRNA inactivation or methylation. Clearly, if one hopes to
consistently achieve long-term transgene expression within the
ear, which will be critical for application of this technique in
humans, this variable will need to be better understood and
controlled, particularly at later ages of delivery.
It is interesting to note that the lower dose of virus used for
most of the studies performed (0.6 ml), delivered at P10–P12,
caused VGLUT3 expression in only 40% of IHCs (Figures 1D
and 1E), and yet this was enough to restore ABR thresholds to
WT levels for click responses and to near normal for pure tone
thresholds (Figures 3A–3C). Similar results have been docu-
mented in other models of hearing recovery after noise exposure
(Kujawa and Liberman, 2009; Lin et al., 2011), in which even
‘‘reversible’’ noise exposure with recovery of auditory thresholds
leads to long-term afferent nerve terminal degeneration while
retaining ‘‘normal’’ auditory thresholds. Similar findings with re-
gard to the discrepancy of ABR threshold and amplitudes have
also been shown from mutant mice lacking synaptic ribbons
(Buran et al., 2010). However, correlative studies in human
temporal bones suggest that cochlear implants in humans can
still function very effectively despite significant spiral ganglion
neuron loss, allowing for meaningful speech and sound trans-
mission (Gassner et al., 2005; Khan et al., 2005). Thus, complete
normalization of all cellular abnormalities may ultimately not berequired for the technique to be successful in humans, though
this should remain a goal for animal studies going forward.
The KO mice develop an unusual appearing ribbon that is thin
and elongated, as noted here and previously (Seal et al., 2008). A
similar ribbon morphologic pattern, flat and plate-like, is seen in
the Otoferlin KO mouse (Roux et al., 2006). As Otoferlin is also
critical in glutamate release at the IHC synapse, this implies
that lack of physiologic activity of the synapse results in such
a flat ribbon appearance. In the rescued mice, while the ribbon
itself appeared normal, we did still see a mixture of elongated
and circular vesicles within the transfected IHCs, as opposed
to all circular in theWT and all elongated in the KOmice, implying
that there may still be differences in transmitter release in the
rescued versus WT mice.
Another interesting finding with regard to the ribbon synapse
was the larger numbers of synaptic vesicles that were associ-
ated with the ribbon seen in the rescued mice, as well as the
mixture of elongated and circular vesicles observed. The data
shows that much larger quantities of VGLUT3 mRNA are being
produced in the rescued as compared to theWTmice (Figure 1C,
RT-PCR data) and suggests, though does not prove, an associ-
ation between increased mRNA levels and vesicle number. We
believe that circular vesicles represent properly packaged vesi-
cles, while the elongated vesicles are improperly packaged
vesicles. Perhaps continuous production of VGLUT3 by theNeuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc. 289
Figure 6. Partial Normalization of Synaptic Ribbon Morphology in the Rescued Mice
Electron microscopy was performed on broken serial thin sections of the synaptic region of the IHCs, which were cut in a horizontal plane parallel to the basilar
membrane in the same orientation for the WT, KO, and rescued KO mice. As previously reported (Seal et al., 2008), VGLUT3 KO mice demonstrate abnormally
thin, elongated ribbons in IHC synapses (middle column), as compared to WT littermates (left column). In the rescued mice (right column, single ribbon shown on
top, double on the bottom), ribbon synapses are normal appearing, taking on amore rounded shape similar to theWT. Black arrows point to the normal or circular
synaptic vesicles and white arrows point to elongated synaptic vesicles.
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duction prevents the IHC from properly packaging the vesicles
at a normal rate, leading to a higher number as well as a mixture
of regular and irregular-appearing vesicles. Another possibility
is that the incomplete transfection rate of IHCs (40% of IHCs
labeled at the doses used for these morphology studies) led to
the heterogeneity of the ribbon morphology seen.
The observed growth on behavioral and electrical measures
seen with bilateral, as opposed to unilateral, rescue (RWM
delivery at P10–P12; Figure 4) was an unexpected finding. While
none of the animals had complete normalization of ABR ampli-
tude and startle-response levels, the amplitude growth does
imply that bilateral input increases the auditory response cen-
trally. An analogous phenomenon is seen with ‘‘binaural summa-
tion’’ and clinically in patients who wear two hearing aids as
opposed to one and report lower levels of amplification required
(Noble, 2010; Steven Colburn et al., 2006) and suggests that the
response seen in these studies is physiologic. Recent studies
have localized VGLUT3 to various structures in the brainstem,
including cochlear nucleus (Fyk-Kolodziej et al., 2011) as well
as the LSO and MNTB (Lee et al., 2011). It is certainly possible
that deficits within auditory brainstem signal pathways could
be contributing to the inability to restore the startle response to
WT levels.
The failure of the technique to reverse the spiral ganglion cell
loss seen in the VGLUT3 KO mice when delivered at P10–P12
is not surprising (Figure 5), given that hair cell activity and afferent290 Neuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc.stimulation can provide a trophic effect on SG survival. This is
probably at least partly due to the fact that virus was delivered
at P10 with subsequent ABR threshold recovery at P17–
P24, after spiral ganglion neuronal degradation has begun
(Seal et al., 2008). This also implies that in order for SG neurons
to be preserved at normal levels, intervention would probably
have to occur earlier. Further, with only 40% of IHCs express-
ing VGLUT3 (using the lower concentration of virus, delivered at
P10–P12), there are still many spiral ganglion neurons not
receiving afferent input, which also probably impacts this result
as well. Wewere thus surprised that even earlier delivery of virus,
at P1–P3, which resulted in relatively early onset of hearing,
measureable by P14, with 100% of IHC expressing VGLUT3,
also did not lead to restoration of SG cell counts to WT levels.
Perhaps there are in utero factors that also help maintain SG
numbers, or even a small delay in hearing onset can lead to
SG loss.
Lastly, while the mutant mouse in the current study and the
hearing loss described in patients with DFNA25 are both due
to mutations in the gene coding for VGLUT3, the comparison
may not be straightforward. First, it is not certain that the
missense mutation described in SLC17A8 is the cause of the
hearing loss seen in DFNA25, though a strong correlation was
observed (Ruel et al., 2008). Second, the null mutation studied
in these experiments would represent a much more severe
phenotype than the missense mutation described as potentially
causative for DNFA25. Thus, whether this technique could
Table 1. Transmission Electron Micrographic Analysis of the
Ribbon Synapse
WT KO Rescued KO
Number of inner hair
cells examined
58 50 61
Total number of
ribbons
18 20 18
Number of floating
ribbons
3 3 4
Number of normal
ribbons
18 0 17
Number of elongated
ribbons
0 20 1
Average number of
synaptic vesicles
associated with the
ribbon
14.44 ± 1.92 16.26 ± 2.85 19.17 ± 4.52
Shape of the synaptic
vesicles
All circular All elongated Mixture of
circular +
elongated
Average number of
docked synaptic
vesicles
2.28 ± 1.27 1.56 ± 0.92 2 ± 0.84
This analysis compares the ribbon synapse and vesicles inWT versus KO
versus AAV1-VGLUT3-rescued KO mice. Electron microscopy was per-
formed on broken serial thin sections of the synaptic region of the
IHCs, which were cut in a horizontal plane parallel to the basilar
membrane with identical handling and orientation for the WT, KO, and
rescued KO. When differentiating vesicles as either ‘‘circular’’ or ‘‘elon-
gated,’’ a vesicle was defined as ‘‘circular’’ when the perpendicular diam-
eters were found to bewithin 50%of each other. Any vesicle with unequal
perpendicular dimensions (>50% difference) was counted as ‘‘elon-
gated,’’ and any ribbon synaptic body that had a length greater than three
times its greatest width was considered to be ‘‘abnormal’’ in appearance.
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unclear. Despite these differences, as our study documents
restoration of normal ABR levels in such a null mutant model, it
nonetheless represents an important initial step for the potential
treatment of inherited deafness.
EXPERIMENTAL PROCEDURES
Animals
VGLUT3 null mutant mice were generated as described in a C57 (Seal et al.,
2008) strain then backcrossed with FVB mice (less than seven generations)
to obtain a homogeneous genetic background. P1–P12 mice were used for
AAV1-VGLUT3 delivery. All procedures and animal handling complied with
NIH ethics guidelines and approved protocol requirements at the University
of California, San Francisco (IACUC).
All surgical procedures were done in a clean, dedicated space. Instruments
were thoroughly cleaned with 70% ETOH and autoclaved prior surgery.
Surgery was carried out under a Leica MZ95 dissecting scope and animals
were situated with neck extended over solid support. Mice were anesthetized
by intraperitoneal injection of a mixture of ketamine hydrochloride (Ketaset,
100 mg/kg), xylazine hydrochloride (Xyla-ject, 10 mg/kg), and acepromazine
(2 mg/kg) and boosted with one-fifth the original dose as required. Depth
of anesthesia was continuously checked by deep tissue response to toe
pinch. Body temperature was maintained with a heating pad and monitored
with a rectal probe throughout procedures. Preoperatively and every 24 hr
postoperatively, animals were given subcutaneous carprofen analgesia(2 mg/kg) to manage inflammation and pain. Animals were closely monitored
for signs of distress and abnormal weight loss postoperatively.
AAV1-VGLUT3 Viral Construct
Mouse VGLUT3 cDNA was subcloned into the multiple cloning site of vector
AM/CBA-WPRE-BGH (kindly provided by R. Palmiter). Human embryonic
kidney 293 cells were cotransfected with three plasmids—AAV-mVGLUT3
plasmid, appropriate helper plasmid-encoding rep and AAV1 cap genes,
and adenoviral helper pF D6—using standard CaPO4 transfection. Cells
were harvested 60 hr after transfection, cell pellets were lysed with sodium
deoxycholate, and AAV vectors were purified from the cell lysate by ultracen-
trifugation through an iodixanol density gradient, then concentrated and
dialyzed against phosphate-buffered saline (PBS), as previously described
(Cao et al., 2009, 2010; Lawlor et al., 2009). Vectors were titered using real-
time PCR (ABI Prism 7700; Applied Biosystems), and purity of vector stocks
was confirmed by running a 10 ml sample on sodium dodecyl sulfate polyacryl-
amide gel electrophoresis and staining with Coomassie blue.
Surgical Procedures
Round Window Membrane Injection
Animalswere anesthetized, the left ear was approached via a dorsal incision as
described by Duan et al. (2004). A small hole was made in the bulla with an
18G needle and expanded as necessary with forceps and the round window
membrane (RWM) was identified. The RWM was gently punctured with a
borosilicate capillary pipette and remained in place until efflux stabilized. A
fixed volume of AAV1-VGLUT3 (0.6 ml or 1.0 ml of a 2.33 1013 vg/ml) previously
drawn into the fine pipette was gently injected through RWM over 1–2 min.
After pulling out the pipette, the RWM niche was quickly sealed with fascia
and adipose tissue. The bulla was sealed with dental cement (Dentemp,
Majestic Drug Company) and the wound was sutured in layers with a 5-0
absorbable chromic suture (Ethicon).
Cochleostomy Delivery
The right ear was approached via ventral, paramedian incision in the neck as
described by Jero et al. (2001). The injection method was similar to the RWM
except that the hole in bulla was made slightly more anterior and larger, to
directly approach the space above the stapedial artery. Injection of virus
was made into the apical turn. We used a 0.5 mm drill bit to gently thin the
bone of the otic capsule where the stria vascularis could be slightly visualized
as a brownish stripe. Once enough bonewas shaved and a slight fluid interface
became visible, 0.6 ml VGLUT3-AAV1 (2.3 3 1013 vg/ml) was pipetted into the
hole over a period of 1–2 min. After application, the hole in the cochlea was
sealed with a small amount of bone wax. After it dried, a small amount of sterile
tissue glue was applied to the bone wax and the bulla was sealed and the
wound was sutured as described above.
Auditory Testing
Acoustic Startle Response Testing
Acoustic startle responses of VGLUT3KO (n = 5),WT littermate (n = 5), rescued
VGLUT3 KO unilateral (n = 5), and rescued VGLUT3 KO bilateral (n = 5) mice
were measured as previously described (Seal et al., 2008). In brief, in darkened
startle chambers (SR-LAB hardware and software, San Diego Instruments),
piezoelectric sensors located under the chambers detect and measure the
peak startle response. Mice were acclimatized to the startle chambers by
presentation of a 70 dB white noise for 5min and then exposed to sound inten-
sities of 100 dB, 110 dB, and 120 dB (each with a 0ms rise time, 40ms plateau,
and 0ms fall time), presented in pseudorandom order with intersound intervals
of 10–50 s. Each run was repeated eight times. Average peak startle amplitude
at each sound level was calculated from eight runs. Final results were calcu-
lated as a percentage of WT mice at the 120 dB presentation level. Statistical
significance between measures was determined using a Student’s t test with
significance defined as p < 0.05.
Auditory Brainstem Response Recording
Sounds were presented and ABRs were tested in free-field conditions as
previously described in a sound-proofed chamber (Akil et al., 2006; Fremeau
et al., 2004). ABR thresholds were determined postoperatively at varying
time points, as early as 4 days after viral delivery for P10–P12 mice. The
mean value of thresholds checked by visual inspection and computer analysisNeuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc. 291
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stimuli.
Compound Action Potential Recording
For the CAP recording, a ventral surgical approach (Jero et al., 2001) was used
to expose the right cochlea 7–14 days after AAV1-VGLUT3 delivery to the inner
ear of the P10–P12mice, including KO (n = 5), rescued KO (n = 8), andWT litter-
mates (n = 5). A fine Teflon-coated silver wire recording electrode was placed
in the round window niche, and the ground electrode was placed in the soft
tissue of the neck. The sound stimulus was generated with Tucker-Davis
System II hardware and software (Tucker-Davis Technologies).
Immunofluorescence
Immunofluorescence studies were conducted similarly for whole-mount and
cochlear sections with the following differences.
Cochlear Whole Mount
Mice cochleaewere perfusedwith 4%PFA in 0.1MPBS (pH7.4) and incubated
in the fixative for 2 hr at 4C. The cochleae were subsequently rinsed with PBS
three times for 10min and thendecalcifiedwith 5%EDTA in 0.1MPBS. Theotic
capsule, the lateral wall, tectorial membrane, and Reissner’s membrane were
removed in that order. The remaining organ of Corti was further dissected into
a surface preparation (microdissected into individual turns), then preincubated
for 1 hr in PBS containing 0.25% Triton X-100 and 5% normal goat serum
(blocking buffer). The whole mount was then incubated with rabbit anti-myosin
VIIa antibody (a hair cell-specificmarker) (Proteus Biosciences Cat 25-6790) at
a dilution of 1:50 in blocking buffer and guinea pig anti-VGLUT3 antibody (a gift
from Dr. Robert Edward, Department of Neurology, UCSF) at 1:5,000. After an
overnight incubation at 4C, the cochlear whole mount was rinsed twice for
10 min with PBS and then incubated for 2 hr in goat anti-rabbit IgG conjugated
to Cy2 and goat anti-guinea pig IgG conjugated to Cy3 diluted to 1:4,000 in
PBS. Specimens were next rinsed in PBS twice for 10 min and mounted on
glass slides in a mounting solution containing DAPI (nucleus stain) and
observed under an Olympus microscope with confocal immunofluorescence.
For inner hair cell counts, the cochlear whole mounts were visualized under
a microscope equipped with epifluorescence, using a 403 objective. To quan-
tify the number of IHC transfected with AAV1-VGLUT3, we labeled specimens
with anti-VGLUT3 antibody, and IHCs were manually counted in the cochlear
whole mount and in the base, midturn, and apex. For GFP labeling, surface
preparation (cochlea whole mount) was incubated with a rabbit anti-GFP anti-
body (Invitrogen A11122) at 1:250. After an overnight incubation at 4C, the
cochlea sections were rinsed twice for 10 min with PBS and then incubated
for 2 hr in goat anti-rabbit IgG conjugated to Cy2 diluted to 1:4,000 in PBS.
They were then rinsed in PBS twice for 10 min and mounted on glass slides
in amounting solution containingDAPI and observed under anOlympusmicro-
scope with confocal immunofluorescence.
Cochlear Sections
Mice were anesthetized and their cochleae were isolated, dissected, perfused
through oval and round windows by 2% paraformaldehyde in 0.1 M PB at
pH 7.4, and incubated in the same fixative for 2 hr. After fixation, the cochleae
were rinsed with PBS and immersed in 5% EDTA in 0.1 M PB for decalcifica-
tion. When the cochleae were completely decalcified, they were incubated
overnight in 30% sucrose for cryoprotection. The cochleae then were
embedded in OCT Tissue Tek Compound (Miles Scientific). Tissues were
cryosectioned at 10–12 mm thickness, mounted on Superfrost microscope
slides (Erie Scientific), and stored at 20C until use. Sections were then
double labeled as described above (see cochlear whole mount). Slides were
then mounted in a 1:1 mixture of PBS and glycerol before being coverslipped.
Slides treated with the same technique but without incubation with the primary
antibody used as a control.
Histology
Light Microscopy
Cochleae were isolated from deeply anesthetized WT, VGLUT3 KO, and
rescued KO mice, perfused through oval and round windows with 2.5% para-
formaldehyde and 1.5% glutaraldehyde in 0.1 M PB at pH 7.4, and incubated
overnight at 4C with slow agitation in fixative. The cochleae were rinsed with
0.1 M PB and postfixed in 1% osmium tetroxide and 1.5% potassium ferricy-
anide (for improved contrast) for 2 hr. The cochleae subsequently were292 Neuron 75, 283–293, July 26, 2012 ª2012 Elsevier Inc.immersed in 5% EDTA (0.2 M). The decalcified cochlea were dehydrated in
ethanol and propylene oxide and embedded in Araldite 502 resin (Electron
Microscopy Sciences) and sectioned at 5 mm. After sections were stained
with toluidine blue, they were mounted in Permount (Fisher Scientific) on
microscope slides.
Electron Microscopy
Electron microscopy was performed as previously described (Akil et al., 2006)
on broken serial thin sections of the synaptic region of the IHCs, which were
cut in a horizontal plane parallel to the basilar membrane. In this study, the
cochleae were all handled and cut exactly the same and the same protocol
and orientation for the WT, KO, and rescued KOwere applied when examining
and visualizing the synaptic ribbons and vesicles. The morphological assess-
ment of ribbons and vesicles was performed as described by Roux et al. (2006)
using 50–61 IHCs and 17–20 different IHC ribbon synapses from three WT,
three KO, and three rescued KO mice. Sections were stained with uranyl
acetate and lead citrate and examined under 60kV in a JEOL-JEM 100S trans-
mission electron microscope. The number of vesicles tethered to the ribbon
included all the vesicles within 30 nm of the ribbon. All the vesicles clearly
located immediately below the ribbon were considered to be docked in our
two-dimensional (2D) estimation.
Spiral Ganglion Cell Counts
Spiral ganglion cell numerical density assessmentwas calculated as described
by Leake et al. (2011) to accurately estimate the number of nuclei in a given
volumeof tissue. For this analysis, threesets of three serial sections (5mmthick-
ness)were collected from the base,midturn, and the apex of fourWT, threeKO,
and four rescued KO cochlea. Adjacent serial sections were compared, and
new nuclei of spiral ganglion neurons that appear in the second section were
counted. Statistical differences were measured using a Student’s t test.
RT-PCR of the Cochlea
Cochlea from WT, VGLUT3 KO, and rescued KO were dissected. The total
RNA was extracted from the whole cochlea, organ of Coti + stria vascularis,
spiral ganglion, and vestibular epithelium (Trizol, Invitrogen) and reverse tran-
scribed with superscript II RNase H (Invitrogen) for 50 min at 42C, using
oligodT primers (Akil et al., 2006). Reactions without the reverse transcriptase
enzyme (RT) were performed as control. Two microliters of RT reaction
product were used for subsequent polymerase chain reaction (PCR; Taq
DNA Polymerase, Invitrogen) of 35 cycles using the following parameters:
94C for 30 s, 60C for 45 s, 72C for 1 min, followed by a final extension of
72C for 10min and storage at 4C. Primers were designed to amplify a unique
sequence of VGLUT3 isoform of 759 bp. The PCR primers that were used for
mouse include VGLUT3 (GenBank accession number AF510321.1: forward-
[gctggaccttctatttgctctta] and reverse- [tctggtaggataatggctcctc]). Analysis of
each PCR sample was then performed on 2% agarose gels containing
0.5 mg/ml ethidium bromide. Gels were visualized using a digital camera and
image processing system (Kodak). Candidate bands were cut out and the
DNA was extracted (Qiaquick gel extraction kit, QIAGEN) and sequenced
(Elim Biopharmaceuticals). The PCR product was then compared directly to
the full VGLUT3 sequence for identity.
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